WebMar 29, 2024 · WATERTOWN, Mass., March 29, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage … WebAug 1, 2024 · LYR-210 is a drug depot, which contains the anti-inflammatory medication mometasone furoate (MF) pre-loaded in a single use applicator. LYR-210 is intended to …
Home - Lyra Medical
WebSep 13, 2024 · Lyra Therapeutics, Inc. is a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, local delivery of medications to diseased tissues not accessible with conventional therapeutic approaches.Lyra's XTreo™ platform is comprised of a biocompatible mesh scaffold, an engineered elastomeric … Web©2024 Lyra Health, Inc. works in partnership with Lyra Clinical Associates P.C. and other contracted partners to be your Lyra Care Navigator Team and deliver clinical services. galaxy s22 ultra 5g screen protector neo flex
Lyra Therapeutics Announces First Patient Treated in Phase 2 …
WebJan 17, 2024 · News Releases. Year. 2024. Feb 27, 2024. Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer. PDF Version. Feb 06, 2024. Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients. PDF Version. WebLyra to hold a conference call to discuss the trial results today at 8:30 a.m. ET. ... The LANTERN study was a randomized, patient blinded, controlled clinical trial designed to evaluate the efficacy and safety of LYR-210 in adult patients with CRS, including patients with and without nasal polyps, who had not previously undergone sinus surgery WebFeb 2, 2024 · Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 1) The safety and scientific validity of this study is the responsibility … galaxy s22 ultra 5g specs